MedTrace Logo

In Vivo PET of Synaptic Density in Cognitive Disorders

NCT05384353 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2026-01-08

No results posted yet for this study

Summary

This study will compare the discriminative power of \[18F\]-SynVesT-1 PET and the standard-of-care \[18F\]-FDG PET in different cognitive disorders (Alzheimer's disease, Frontotemporal degeneration, dementia with Lewy bodies and late-life psychiatric disorders). Moreover, changes in \[18F\]-SynVesT-1 PET will be evaluated as well as their correlation with specific symptomatology.

Conditions

  • Alzheimer Disease
  • Frontotemporal Degeneration
  • Dementia With Lewy Bodies
  • Psychiatric Disorder

Interventions

OTHER

[18F]-SynVesT-1

PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Koen Van Laere, MD, PhD, DSc · UZ/KU Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2025-05-28
Completion
2025-06-04

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05384353 on ClinicalTrials.gov